NEXPRING HEALTH EX HAMILTON THORNE acquired by ASTORG

Led by the pan-European private equity firm Astorg alongside reinvesting shareholders FAX Capital and Daniel Thorne, this transaction secures the complete acquisition and subsequent privatization of Hamilton Thorne, facilitating its immediate merger with Cook Medical's reproductive health division to establish Nexpring Health. Announced in July 2024 and executed through the acquirer's eighth generation flagship fund (Astorg VIII), the definitive arrangement agreement successfully delists the target entity from the Toronto Stock Exchange. The financial architecture governing the buyout relies on a comprehensive cash consideration mechanism to facilitate the total transfer of ownership for all outstanding common shares. To strategically anchor the newly consolidated MedTech platform, historical stakeholders executed significant capital roll-overs; specifically, FAX Capital and affiliated entities reinvested their entire 11.5% equity position while securing an option to inject an additional US$10 million directly into the combined structure. The strategic rationale driving this massive sector consolidation is explicitly centered on engineering a scaled, undisputed global leader in the highly fragmented Assisted Reproductive Technology market. By simultaneously carving out the complementary reproductive assets from Cook Medical, the acquiring sponsor actively merges two distinct technological portfolios to capture surging international demand for standardized fertility treatments. The institutional capital deployed will finance a unified integration roadmap, aligning disparate commercial channels and research pipelines under a singular corporate identity scheduled for formal launch in 2025. Furthermore, the private equity sponsor has already aggressively leveraged this newly established platform to initiate immediate external growth, signing a definitive agreement in January 2025 to carve out and absorb Irvine Scientific's reproductive health division. This bolt-on acquisition definitively broadens the combined group's product suite into the critical vitrification and embryo culture media segments. Ultimately, this multijurisdictional financial operation systematically transforms a publicly traded specialized manufacturer into the cornerstone of a privately held, globally integrated fertility technology conglomerate.